Published • loading... • Updated
Skyrizi's momentum defies J&J's rival Icotyde as AbbVie raises full-year sales guidance
Summary by endpoints.news
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Skyrizi's momentum defies J&J's rival Icotyde as AbbVie raises full-year sales guidance
If AbbVie executives are bothered by growing threats to their immunology powerhouse, they aren't letting on. Earlier this year, analysts were pondering how the company’s blockbuster Skyrizi might fare against competition from ...
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
